KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Change in Receivables: 2011-2025

Historic Change in Receivables for Sarepta Therapeutics (SRPT) over the last 14 years, with Sep 2025 value amounting to -$131.6 million.

  • Sarepta Therapeutics' Change in Receivables fell 276.52% to -$131.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$38.8 million, marking a year-over-year decrease of 133.53%. This contributed to the annual value of $201.7 million for FY2024, which is 8.60% up from last year.
  • Latest data reveals that Sarepta Therapeutics reported Change in Receivables of -$131.6 million as of Q3 2025, which was up 0.39% from -$132.1 million recorded in Q2 2025.
  • Sarepta Therapeutics' 5-year Change in Receivables high stood at $167.5 million for Q4 2024, and its period low was -$132.1 million during Q2 2025.
  • Its 3-year average for Change in Receivables is $16.5 million, with a median of $13.0 million in 2023.
  • As far as peak fluctuations go, Sarepta Therapeutics' Change in Receivables spiked by 3,598.81% in 2023, and later slumped by 602.20% in 2025.
  • Quarterly analysis of 5 years shows Sarepta Therapeutics' Change in Receivables stood at $3.2 million in 2021, then spiked by 309.58% to $13.1 million in 2022, then surged by 521.02% to $81.5 million in 2023, then skyrocketed by 105.55% to $167.5 million in 2024, then crashed by 276.52% to -$131.6 million in 2025.
  • Its Change in Receivables stands at -$131.6 million for Q3 2025, versus -$132.1 million for Q2 2025 and $57.4 million for Q1 2025.